...
首页> 外文期刊>British Journal of Cancer >The hollow fibre assay as a model for in vivo pharmacodynamics of fluoropyrimidines in colon cancer cells
【24h】

The hollow fibre assay as a model for in vivo pharmacodynamics of fluoropyrimidines in colon cancer cells

机译:中空纤维测定作为氟嘧啶在结肠癌细胞中体内药效学的模型

获取原文
   

获取外文期刊封面封底 >>

       

摘要

The Hollow Fibre Assay (HFA) is usually applied as an early in vivo model for anti-cancer drug screening, but is potentially an excellent model for short-term in vivo pharmacodynamic studies. We used the model to study the in vivo role of thymidine phosphorylase/platelet-derived endothelial cell growth factor (TP/PD-ECGF) in the cytotoxicity and pharmacodynamics of TAS-102 in colon cancer cells. TAS-102 is a new oral drug formulation, which is composed of trifluorothymidine (TFT) and thymidine phosphorylase inhibitor (TPI), which prevents TFT degradation. We compared the activity with Xeloda (capecitabine), which is activated by TP into 5FU. Hollow fibres filled with human Colo320 or Colo320TP1 colorectal cancer cells with deficient or high TP expression, respectively, were implanted subcutaneously (s.c.) at both flanks of BALB/c mice. The mice were treated orally over 5 days with TAS-102, TFT alone, 5′DFUR±TPI or capecitabine at their maximum tolerated dose (MTD). The cells were retrieved from the fibres and assayed for growth (MTT assay), cell cycle distribution (flow cytometry) and apoptosis induction (FragEL method). TAS-102 induced considerable growth inhibition (50%, P8-fold), which was more pronounced in Colo320 than in Colo320TP1. Again, omission of TPI neutralised the effect of TAS-102. Similarly, 5′DFUR and capecitabine induced a significant G2M-phase arrest (up to 45%) in the Colo320TP1 cell line, but less pronounced in the parental Colo320. Addition of TPI to 5′DFUR reduced this effect to control levels. Also induction of apoptosis was reduced in the presence of TPI. The data demonstrated that the HFA is excellently suited for studying short-term pharmacodynamic effects of fluoropyrimidines in vivo. TAS-102 is only effective in inducing cytotoxicity when systemic TPI is present, but acts against both low and high TP expressing colon cancer cells, while 5′DFUR needs cellular TP to exert significant activity.
机译:空心纤维测定法(HFA)通常用作抗癌药物筛选的早期体内模型,但可能是短期体内药效学研究的优秀模型。我们使用该模型研究了胸苷磷酸化酶/血小板源性内皮细胞生长因子(TP / PD-ECGF)在TAS-102在结肠癌细胞中的细胞毒性和药效学中的体内作用。 TAS-102是一种新型口服药物制剂,由三氟胸苷(TFT)和可防止TFT降解的胸苷磷酸化酶抑制剂(TPI)组成。我们将活性与希罗达(卡培他滨)进行了比较,后者被TP激活为5FU。将分别填充有缺乏或高TP表达的人Colo320或Colo320TP1结直肠癌细胞的空心纤维皮下植入(s.c.)到BALB / c小鼠的两个侧面。用TAS-102,单独的TFT,5'DFUR±TPI或卡培他滨以最大耐受剂量(MTD)对小鼠进行5天的口服治疗。从纤维中回收细胞,并对其生长(MTT测定),细胞周期分布(流式细胞仪)和凋亡诱导(FragEL法)进行测定。 TAS-102诱导了相当大的生长抑制(50%,P8倍),在Colo320中比在Colo320TP1中更明显。同样,省略TPI可中和TAS-102的作用。同样,5'DFUR和卡培他滨在Colo320TP1细胞系中诱导了显着的G2M期阻滞(高​​达45%),但在亲本Colo320中不明显。在5'DFUR中添加TPI可将这种影响降低到控制水平。在TPI存在下,凋亡的诱导也减少了。数据表明,HFA非常适合研究氟嘧啶在体内的短期药效作用。 TAS-102仅在存在全身性TPI时有效诱导细胞毒性,但同时对表达高和低TP的结肠癌细胞都有作用,而5'DFUR需要细胞TP发挥重要活性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号